130 related articles for article (PubMed ID: 18980977)
1. Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization.
Gallagher EM; O'Shea DM; Fitzpatrick P; Harrison M; Gilmartin B; Watson JA; Clarke T; Leonard MO; McGoldrick A; Meehan M; Watson C; Furlong F; O'Kelly P; Fitzpatrick JM; Dervan PA; O'Grady A; Kay EW; McCann A
Clin Cancer Res; 2008 Nov; 14(21):6829-38. PubMed ID: 18980977
[TBL] [Abstract][Full Text] [Related]
2. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues.
Jarrard DF; Bussemakers MJ; Bova GS; Isaacs WB
Clin Cancer Res; 1995 Dec; 1(12):1471-8. PubMed ID: 9815946
[TBL] [Abstract][Full Text] [Related]
3. [Genomic imprinting of insulin-like growth factor II in prostate cancer and its clinical significance].
Liu ZW; Zhou FJ; Luo YM; Qin ZK; Wang DJ; Luo JH; Han H; Li YH; Wang H
Ai Zheng; 2006 Jun; 25(6):765-70. PubMed ID: 16764778
[TBL] [Abstract][Full Text] [Related]
4. Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder.
Meehan M; Melvin A; Gallagher E; Smith J; McGoldrick A; Moss C; Goossens S; Harrison M; Kay E; Fitzpatrick J; Dervan P; Mc Cann A
Genes Chromosomes Cancer; 2007 Jun; 46(6):587-93. PubMed ID: 17366617
[TBL] [Abstract][Full Text] [Related]
5. Developmentally imprinted genes as markers for bladder tumor progression.
Cooper MJ; Fischer M; Komitowski D; Shevelev A; Schulze E; Ariel I; Tykocinski ML; Miron S; Ilan J; de Groot N; Hochberg A
J Urol; 1996 Jun; 155(6):2120-7. PubMed ID: 8618347
[TBL] [Abstract][Full Text] [Related]
6. [Loss of imprinting of insulin-like growth factor II gene in acute myeloid leukemia].
Liu Y; Yang B; Zhu H; Wang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Feb; 17(1):39-41. PubMed ID: 10653908
[TBL] [Abstract][Full Text] [Related]
7. Genomic imprinting of insulin-like growth factor-2 in infant leukemia and childhood neuroblastoma.
Hattori H; Matsuzaki A; Suminoe A; Ihara K; Eguchi M; Tajiri T; Suita S; Ishii E; Hara T
Cancer; 2000 May; 88(10):2372-7. PubMed ID: 10820361
[TBL] [Abstract][Full Text] [Related]
8. Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma.
Nonomura N; Nishimura K; Miki T; Kanno N; Kojima Y; Yokoyama M; Okuyama A
Cancer Res; 1997 Jul; 57(13):2575-7. PubMed ID: 9205056
[TBL] [Abstract][Full Text] [Related]
9. Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer.
Liou JM; Wu MS; Lin JT; Wang HP; Huang SP; Chiu HM; Lee YC; Lin YB; Shun CT; Liang JT
Eur J Cancer; 2007 May; 43(8):1276-82. PubMed ID: 17382534
[TBL] [Abstract][Full Text] [Related]
10. Loss of imprinting in IGF2 in colorectal carcinoma assessed by microdissection.
Maenaka S; Hikichi T; Imai MA; Minamoto T; Kawahara E
Oncol Rep; 2006 Apr; 15(4):791-5. PubMed ID: 16525660
[TBL] [Abstract][Full Text] [Related]
11. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
12. Genomic imprinting of insulin-like growth factor 2 (IGF-2) in chronic synovitis.
Möller B; Kerschbaumer G; Komor M; Kerschbaumer F; Ottmann OG; Hoelzer D; Hofmann WK
Growth Horm IGF Res; 2007 Dec; 17(6):500-5. PubMed ID: 17590364
[TBL] [Abstract][Full Text] [Related]
13. LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR.
Xu W; Fan H; He X; Zhang J; Xie W
J Exp Clin Cancer Res; 2006 Dec; 25(4):543-7. PubMed ID: 17310846
[TBL] [Abstract][Full Text] [Related]
14. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon.
Mineo R; Fichera E; Liang SJ; Fujita-Yamaguchi Y
Biochem Biophys Res Commun; 2000 Feb; 268(3):886-92. PubMed ID: 10679300
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor.
Bernard-Pierrot I; Ricol D; Cassidy A; Graham A; Elvin P; Caillault A; Lair S; Broët P; Thiery JP; Radvanyi F
Oncogene; 2004 Dec; 23(57):9201-11. PubMed ID: 15516981
[TBL] [Abstract][Full Text] [Related]
16. Loss of imprinting and promoter usage of the IGF2 in laryngeal squamous cell carcinoma.
Grbesa I; Ivkic M; Pegan B; Gall-Troselj K
Cancer Lett; 2006 Jul; 238(2):224-9. PubMed ID: 16111804
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.
Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Ntinis A; Moreas I; Vasou O; Koutselini H; Patsouris E
Anticancer Res; 2009 Oct; 29(10):4163-7. PubMed ID: 19846967
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
19. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A
J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525
[TBL] [Abstract][Full Text] [Related]
20. [Insulin-like growth factor 2 imprinting status and promoter usage in the placenta of macrosomia].
Yao JC; Hu YL; Wang ZQ; Dai YM; Ling JX; Ye XD
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):309-14. PubMed ID: 17673042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
